AR076550A1 - Inhibidores de la janus tirosina kinasa (jak) - Google Patents
Inhibidores de la janus tirosina kinasa (jak)Info
- Publication number
- AR076550A1 AR076550A1 ARP100101558A ARP100101558A AR076550A1 AR 076550 A1 AR076550 A1 AR 076550A1 AR P100101558 A ARP100101558 A AR P100101558A AR P100101558 A ARP100101558 A AR P100101558A AR 076550 A1 AR076550 A1 AR 076550A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- aryl
- heteroalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compuestos de formula 1 y tautomeros y sales de los mismos farmacéuticamente aceptables que son inhibidores selectivos de JAK. También se refiere a intermediarios que se utilizan para hacer dichos compuestos, a la preparacion de un compuesto con dichas características, a composiciones farmacéuticas que lo contienen, a métodos para inhibir la actividad de la JAK, y a métodos para impedir o tratar varias condiciones mediadas por lo menos en parte por la actividad de la JAK. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o un tautomero o sales farmacéuticamente aceptables del mismo, donde Y1 es N o CR1c; R1a es (a) cicloalquilo C3-8, opcionalmente sustituido con entre 1 y 3 sustituyentes R1d donde cada R1d se selecciona independientemente entre el grupo que consiste en alquilo C1-8, alquenilo C2-8, alquinilo C2-8, hidroxilo, halogeno, heteroalquilo C1-8, ciano, arilo, heteroarilo, heterociclilo y heterociclilcarbonilo; o si se encuentran en átomos de carbono adyacentes del cicloalquilo C3-8, se pueden combinar con los átomos a los cuales están unidos para formar un grupo arilo; (b) alquilo C1-8, opcionalmente sustituido con entre 1 y 3 sustituyentes seleccionados entre el grupo que consiste en alquenilo C2-8, alquinilo C2-8, amino, hidroxilo, halogeno, heteroalquilo C1-8, ciano, cicloalquilo C3-8, arilo, haloarilo, alquilarilo C1-8, alcoxiarilo C1-8, heteroarilo, heterociclilo C3-8 y heterociclilcarbonilo C3-8; (c) heterociclilo, opcionalmente sustituido con entre 1 y 3 sustituyentes seleccionados entre el grupo que consiste en alquilo C1-8, alquenilo C2-8, alquinilo C2-8, hidroxilo, halogeno, heteroalquilo C1-8, ciano, arilo, heteroarilo, heterociclilo y heterociclilcarbonilo; (c) arilo, opcionalmente sustituido con entre 1 y 3 sustituyentes seleccionados entre el grupo que consiste en aIquilo C1-8, alquenilo C2-8, alquinilo C2-8, hidroxilo, halogeno, heteroalquilo C1-8, ciano, arilo, heteroarilo, heterociclilo y heterociclilcarbonilo, amino y alquilsulfonilo; y (d) heteroarilo, opcionalmente sustituido con entre 1 y 3 sustituyentes seleccionados entre el grupo que consiste en alquilo C1-8, alquenilo C2-8, alquinilo C2-8, hidroxilo, halogeno, heteroalquilo C1-8, ciano, arilo, heteroarilo, heterociclilo y heterociclilcarbonilo; R1b es H o aIquilo C1-8; R1c es H, alquilo C1-8 o halogeno; R2 es H, alquilo C1-8, heteroalquilo C1-8, heterociclil C1-8alcoxi, halogeno o heterociclilo; R3 es H o alquilo C1-8 o cicloalquilo C3-8; R4 se selecciona entre el grupo formado por amino, alquilo C1-8, amino C1-8alquilo, alquenilo C2-8, alquinilo C2-8, heteroalquilo C1-8, cicloalquilo C3-8, arilo, heteroarilo y heterociclilo C3-8; y m es 0, 1, 2 o 3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17607709P | 2009-05-06 | 2009-05-06 | |
US25623909P | 2009-10-29 | 2009-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076550A1 true AR076550A1 (es) | 2011-06-22 |
Family
ID=42558558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101558A AR076550A1 (es) | 2009-05-06 | 2010-05-06 | Inhibidores de la janus tirosina kinasa (jak) |
Country Status (4)
Country | Link |
---|---|
US (2) | US8367689B2 (es) |
AR (1) | AR076550A1 (es) |
TW (1) | TW201040162A (es) |
WO (1) | WO2010129802A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
WO2009145856A1 (en) * | 2008-04-16 | 2009-12-03 | Portola Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2481411A1 (en) * | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib |
KR102055532B1 (ko) | 2011-04-22 | 2019-12-12 | 시그날 파마소티칼 엘엘씨 | 치환된 디아미노카르복스아미드 및 디아미노카르보니트릴 피리미딘, 그의 조성물, 및 그를 사용하는 치료 방법 |
WO2013054351A1 (en) * | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
AU2012318896B2 (en) | 2011-10-03 | 2017-03-02 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
EP2763975B1 (en) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
US9006444B2 (en) | 2011-10-05 | 2015-04-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
US9216173B2 (en) | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
KR102019530B1 (ko) | 2011-11-23 | 2019-09-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 피라진 키나아제 저해제 |
AU2012357038B2 (en) * | 2011-12-23 | 2016-05-12 | Cellzome Limited | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
AU2013266438B2 (en) * | 2012-05-22 | 2017-09-07 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
BR112014029310A2 (pt) * | 2012-05-24 | 2018-06-26 | Cellzome Ltd | análogos da pirimidina heterocíclica como inibidores da tyk2 |
US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
CA2890935A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
HUE033448T2 (en) | 2013-08-07 | 2017-11-28 | Cadila Healthcare Ltd | Janus kinase inhibitor N-cyanomethylamides |
WO2015039613A1 (zh) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
US9382246B2 (en) | 2013-12-05 | 2016-07-05 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
WO2015095444A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US9775839B2 (en) | 2014-03-13 | 2017-10-03 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
EP3129379A4 (en) | 2014-04-11 | 2017-09-13 | The University of North Carolina at Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
US9796685B2 (en) | 2014-12-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide |
ES2882954T3 (es) | 2014-12-16 | 2021-12-03 | Signal Pharm Llc | Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel |
EP3250557A4 (en) | 2015-01-29 | 2018-06-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
CN104987324B (zh) * | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
WO2017019487A1 (en) | 2015-07-24 | 2017-02-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
AU2016363005A1 (en) | 2015-12-04 | 2018-07-05 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
JP7041070B2 (ja) * | 2016-04-15 | 2022-03-23 | エピザイム,インコーポレイティド | Ehmt1およびehmt2阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
KR20190092542A (ko) * | 2016-12-19 | 2019-08-07 | 에피자임, 인코포레이티드 | Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물 및 이의 사용 방법 |
CA3060416A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
JP7324778B2 (ja) | 2018-05-04 | 2023-08-10 | ポートラ ファーマシューティカルズ, エルエルシー | セルデュラチニブ(cerdulatinib)の固体形態 |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
JP2022537877A (ja) * | 2019-04-30 | 2022-08-31 | セルジーン コーポレイション | アプレミラストおよびtyk2阻害剤を含む併用療法 |
EP4253375A1 (en) * | 2020-11-26 | 2023-10-04 | Artivila (ShenZhen) Innovation Center, Ltd. | Amide compound, pharmaceutical composition and use thereof |
WO2022166916A1 (zh) * | 2021-02-05 | 2022-08-11 | 深圳市塔吉瑞生物医药有限公司 | 取代的杂芳基衍生物及其组合物及用途 |
WO2023043630A1 (en) * | 2021-09-16 | 2023-03-23 | Lomond Therapeutics, Inc. | Compounds having n-arylpyrimidin-2-amine derivatives as therapeutic agents |
TW202329961A (zh) * | 2021-11-30 | 2023-08-01 | 日商興和股份有限公司 | 新穎菸鹼醯胺化合物及其用途 |
WO2023218245A1 (en) * | 2022-05-13 | 2023-11-16 | Voronoi Inc. | Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69839735D1 (de) | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
NZ537752A (en) * | 2002-07-29 | 2006-12-22 | Rigel Pharmaceuticals Inc | Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases |
ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
KR101216372B1 (ko) | 2004-03-30 | 2013-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Jak 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌 |
US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
ES2337496T3 (es) | 2005-01-19 | 2010-04-26 | Rigel Pharmaceuticals, Inc. | Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos. |
AU2006309013B2 (en) * | 2005-11-01 | 2012-06-28 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
JP2009544592A (ja) * | 2006-07-21 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Jakキナーゼ阻害剤としての2,4−ジ(アリールアミノ)−ピリミジン−5−カルボキサミド化合物 |
US20100204231A1 (en) | 2007-05-04 | 2010-08-12 | Astrazeneca Ab | Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer |
WO2009145856A1 (en) * | 2008-04-16 | 2009-12-03 | Portola Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
US8063058B2 (en) * | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US8138339B2 (en) * | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2986640C (en) * | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
BRPI0920966B1 (pt) * | 2008-11-28 | 2022-03-03 | Kowa Company Ltd | Derivado de piridina-3-carboxiamida, seu uso, inibidor de jak3 e composição farmacêutica |
US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
-
2010
- 2010-05-06 US US12/775,358 patent/US8367689B2/en active Active
- 2010-05-06 WO PCT/US2010/033921 patent/WO2010129802A1/en active Application Filing
- 2010-05-06 TW TW099114720A patent/TW201040162A/zh unknown
- 2010-05-06 AR ARP100101558A patent/AR076550A1/es unknown
-
2012
- 2012-12-17 US US13/717,569 patent/US8853230B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20130137673A1 (en) | 2013-05-30 |
US8853230B2 (en) | 2014-10-07 |
TW201040162A (en) | 2010-11-16 |
US20110005947A1 (en) | 2011-01-13 |
WO2010129802A1 (en) | 2010-11-11 |
US8367689B2 (en) | 2013-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
AR097024A1 (es) | Derivados sustituidos de quinazolin-4-ona | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR071452A1 (es) | Inhibidores de hsp90 | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
EA201390884A1 (ru) | Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса | |
AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
UA109792C2 (uk) | Індоли як противірусні агенти відносно респіраторного синтиціального вірусу | |
TN2009000199A1 (en) | Heteromonocyclic compound and use thereof | |
NO20080391L (no) | Pyrazolbaserte LXR modulatorer | |
CL2008002794A1 (es) | Compuestos derivados de dihidropirimidina-2,4-(1h,3h)-diona; formas cristalinas, compuestos intermediarios; procedimiento de preparación de los compuestos intermediarios, composición farmacéutica; y su uso util para tratar hepatitis c en un mamífero. | |
AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
AR065280A1 (es) | Agentes antiparasitarios | |
CY1122182T1 (el) | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες | |
AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP | |
AR072225A1 (es) | Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlos | |
AR100530A1 (es) | Compuestos antihelmínticos | |
ATE409179T1 (de) | Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten | |
AR071925A1 (es) | Malonamidas como antagonistas de orexina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |